Asia Pacific Liver Disease Treatment Market is segmented By Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy Drugs), By Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Liver Cancer, Genetic Disorder, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers, Others), By Country (India., China, Japan) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Asia Pacific Liver disease treatment market reached US$ 3.84 billion in 2023 and is expected to reach US$ 5.83 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.
The liver disease treatment market is expanding rapidly, driven by the increasing prevalence of liver disorders such as hepatitis, fatty liver disease, and cirrhosis. Factors such as rising alcohol intake, obesity rates, and viral infections all contribute to this trend, creating a greater need for appropriate treatment solutions. The industry offers a wide range of medicines, including antiviral drugs, immunosuppressants, and new gene therapies.
Recent advances in biotechnology and pharmaceuticals have fueled innovation, with many corporations investing in research and development of new medications. This includes medications that target specific pathways involved in liver disease progression, which raises the prospect of more tailored and effective treatments. Furthermore, the growing focus on preventative interventions and early diagnosis is altering market dynamics, with healthcare providers increasingly.
Market Scope
|
Metrics |
Details |
|
CAGR |
5.5% |
|
Market Size |
2022-2031 |
|
Market Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Disease Type, Treatment Type, and End-User |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of liver diseases
The rising prevalence of liver diseases propels the market growth. For instance, according to the National Viral Hepatitis Control Program, anti-Hepatitis C virus antibody prevalence in the general population is estimated to be between 0.09 to 15%. Based on some regional-level studies, it is estimated that there are 6-12 million people with Hepatitis C in India.
Moreover, according to an article posted by Tropical Medicine and Health in August 2023, hepatitis is a major public health issue in Pakistan, with an estimated 11.55% prevalence of HCV infection in the adult population. The country ranks second globally in terms of hepatitis C virus (HCV) infections, with approximately one in every 20 Pakistanis already infected.
Moreover, according to the World Health Organization, it is estimated that Cambodia has a prevalence of hepatitis C between 2.0 and 2.9%. The prevalence of the hepatitis C (anti-HCV positive) ranged from 0.87 to 14.7%. In India, as per the latest estimates, 40 million people are chronically infected with hepatitis B and six to 12 million people are chronically infected with hepatitis C.
Restraints
Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. The higher costs of drugs that are associated with the treatment of various liver diseases affect the affordability for many people and this acts as a restraint to the Asia Pacific Liver disease treatment market.
Market Segment Analysis
The Asia Pacific liver disease treatment market is segmented based on disease type, treatment type, and end-user.
The segment non-alcoholic fatty liver disease accounted for approximately 42.8% of the Asia Pacific liver disease treatment market share.
The non-alcoholic fatty liver disease segment is expected to hold the largest market share over the forecast period. In this segment, the increasing prevalence and recent treatment approvals would drive this market.
Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in your liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes fat to build up in the liver, this condition is called alcohol-associated liver disease. Two types of NAFLD are nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). People typically develop one type of NAFLD or the other, although sometimes people with one form are later diagnosed with the other form of NAFLD.
For instance, according to the National Institute of Health, the prevalence of adult NAFLD in India has been reported between 6.7% and 55.1%. Of all cases with an asymptomatic elevation of liver enzymes, NAFLD may be responsible for almost one-third. Furthermore, explant histology data from liver transplant centers suggest that two-thirds of the patients with ‘cryptogenic’ cirrhosis had NAFLD. The prevalence of pediatric NAFLD in India varies from 7.3% to 22.4% in the healthy population. The prevalence of NAFLD increases with age.
Market Segmentation
By Disease Type
- Hepatitis
- Autoimmune Diseases
- Non-Alcoholic Fatty Liver Disease
- Liver Cancer
- Genetic Disorder
- Others
By Treatment Type
- Antiviral Drugs
- Sofosbuvir
- Ombitasvir
- Immunosuppressants
- Vaccines
- Hepatitis B vaccine
- Hepatitis A vaccine
- Combined hepatitis A and B vaccine
- Immunoglobulins
- Corticosteroids
- Prednisone
- Targeted Therapy
- Sorafenib
- Regorafenib
- Chemotherapy Drugs
- Nivolumab
- Pembrolizumab
By End-User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
Market Competitive Landscape
The major global players in the Asia Pacific liver disease treatment market include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Zydus Group, Lupin, Mankind Pharma, Torrent Pharmaceuticals Ltd., AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd among others.
Key Developments
- In February 2024, Immune-Onc Therapeutics entered into a clinical trial partnership with Roche for a Phase Ib/II clinical trial of IO-108 plus atezolizumab and bevacizumab to treat hepatocellular carcinoma (HCC), the most common type of liver cancer. IO-108 is a LILRB2-directed antibody of Immune-Onc while atezolizumab and bevacizumab are Roche’s cancer immunotherapy combination regimen.
Why Purchase the Report?
- To visualize the Asia Pacific liver disease treatment market segmentation based on disease type, treatment type, and end-user as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of Asia Pacific liver disease treatment market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The Asia Pacific liver disease treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
